強生(JNJ.US)宣佈EGFR/c-MET雙抗「埃萬妥單抗」在國內獲批一項新適應症

智通財經

2025/08/08

智通財經APP獲悉，8月8日，強生(JNJ.US)宣佈EGFR/c-MET雙抗「埃萬妥單抗」(Amivantamab)在國內獲批一項新適應症，聯合蘭澤替尼適用於攜帶表皮生長因子受體(EGFR)19號外顯子缺失或21號外顯子L858R置換突變的局部晚期或轉移性非小細胞肺癌(NSCLC)成人患者的一線治療。

2025年2月，該藥首次在國內獲批，用於EGFRex20ins突變NSCLC一線治療。2025年4月，該藥在國內獲批一項新適應症，聯合化療用於EGFRTKI經治後局部晚期或轉移性NSCLC患者治療。本次是埃萬妥單抗在國內獲批的第3項適應症。

埃萬妥單抗最早於2021年5月在美國首次獲得加速批准上市。迄今，圍繞非小細胞肺癌這一重磅癌種，埃萬妥單抗在全球範圍內已獲批4項適應症

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2557527561"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2557527561\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2557527561?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-08-08 21:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2557527561","market":"us","top_or_hot":-1,"title":"強生(JNJ.US)宣佈EGFR/c-MET雙抗「埃萬妥單抗」在國內獲批一項新適應症","media":"智通財經","content":"<html><body><p>智通財經APP獲悉，8月8日，強生(<a href=\"https://laohu8.com/S/JNJ\">JNJ</a>.US)宣佈EGFR/c-MET雙抗「埃萬妥單抗」(Amivantamab)在國內獲批一項新適應症，聯合蘭澤替尼適用於攜帶表皮生長因子受體(EGFR)19號外顯子缺失或21號外顯子L858R置換突變的局部晚期或轉移性非小細胞肺癌(NSCLC)成人患者的一線治療。</p><p><img src=\"https://img.zhitongcaijing.com/image/20250808/1754659176462761.png\" title=\"1754659176462761.png\"/></p><p>2025年2月，該藥首次在國內獲批，用於EGFRex20ins突變NSCLC一線治療。2025年4月，該藥在國內獲批一項新適應症，聯合化療用於EGFRTKI經治後局部晚期或轉移性NSCLC患者治療。本次是埃萬妥單抗在國內獲批的第3項適應症。</p><p>埃萬妥單抗最早於2021年5月在美國首次獲得加速批准上市。迄今，圍繞非小細胞肺癌這一重磅癌種，埃萬妥單抗在全球範圍內已獲批4項適應症</p></body></html>","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>強生(JNJ.US)宣佈EGFR/c-MET雙抗「埃萬妥單抗」在國內獲批一項新適應症</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n強生(JNJ.US)宣佈EGFR/c-MET雙抗「埃萬妥單抗」在國內獲批一項新適應症\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">智通財經</strong><span class=\"h-time small\">2025-08-08 21:18</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body><p>智通財經APP獲悉，8月8日，強生(<a href=\"https://laohu8.com/S/JNJ\">JNJ</a>.US)宣佈EGFR/c-MET雙抗「埃萬妥單抗」(Amivantamab)在國內獲批一項新適應症，聯合蘭澤替尼適用於攜帶表皮生長因子受體(EGFR)19號外顯子缺失或21號外顯子L858R置換突變的局部晚期或轉移性非小細胞肺癌(NSCLC)成人患者的一線治療。</p><p><img src=\"https://img.zhitongcaijing.com/image/20250808/1754659176462761.png\" title=\"1754659176462761.png\"/></p><p>2025年2月，該藥首次在國內獲批，用於EGFRex20ins突變NSCLC一線治療。2025年4月，該藥在國內獲批一項新適應症，聯合化療用於EGFRTKI經治後局部晚期或轉移性NSCLC患者治療。本次是埃萬妥單抗在國內獲批的第3項適應症。</p><p>埃萬妥單抗最早於2021年5月在美國首次獲得加速批准上市。迄今，圍繞非小細胞肺癌這一重磅癌種，埃萬妥單抗在全球範圍內已獲批4項適應症</p></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"http://www.zhitongcaijing.com/content/detail/1327612.html\">智通財經</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4581","symbol_name":"高盛持倉","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1327612.html","article_id":"2557527561","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2557527561","pubTimestamp":1754659109,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通財經APP獲悉，8月8日，強生宣佈EGFR/c-MET雙抗「埃萬妥單抗」在國內獲批一項新適應症，聯合蘭澤替尼適用於攜帶表皮生長因子受體19號外顯子缺失或21號外顯子L858R置換突變的局部晚期或轉移性非小細胞肺癌成人患者的一線治療。本次是埃萬妥單抗在國內獲批的第3項適應症。埃萬妥單抗最早於2021年5月在美國首次獲得加速批准上市。迄今，圍繞非小細胞肺癌這一重磅癌種，埃萬妥單抗在全球範圍內已獲批4項適應症","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4581":"高盛持仓","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","IE00BDGV0183.EUR":"GUINNESS GLOBAL EQUITY INCOME \"C\" (EUR) INC","IE0034235303.USD":"PINEBRIDGE US RESEARCH ENHANCED CORE EQUITY \"A\" (USD) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0795875086.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD","IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","IE00BN8TJ469.HKD":"FTGF CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A\" (HKD) INC","LU2347655156.SGD":"JPMorgan Investment Funds - Global Income A (icdiv) SGD-H","BK4162":"人寿与健康保险","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","LU1674673428.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AC\" (USD) ACC","LU1032466523.USD":"高盛全球多资产收益组合Acc","LU2129689514.USD":"FRANKLIN GLOBAL INCOME \"A\" (USD) INC","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU2129689431.USD":"FRANKLIN GLOBAL INCOME \"A\" (USD) ACC","LU2592432038.USD":"WELLINGTON MULTI-ASSET HIGH INCOME \"A\" (USD) ACC","LU1032955483.USD":"NORDEA 1 STABLE RETURN \"HB\" (USDHDG) ACC","LU2430703095.HKD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4\" (HKD) INC","LU1221951129.SGD":"NORDEA 1 STABLE RETURN \"HM\" (SGDHDG) INC","JNJ":"强生","LU0792757196.USD":"TEMPLETON SHARIAH GLOBAL EQUITY FUND \"A\" (USD) ACC","BK4504":"桥水持仓","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","IE00BVYPNW00.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) ACC","BK4559":"巴菲特持仓","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU2430703251.USD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4\" (USD) INC","LU0345770308.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","BK4568":"美国抗疫概念","LU1066051225.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AC\" (USD) ACC","BK4550":"红杉资本持仓","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU1496350502.SGD":"FRANKLIN DIVERSIFIED DYNAMIC \"A\" (SGDHDG) ACC","LU1732799900.SGD":"JPMorgan Investment Funds - Global Income A (irc) SGD-H","LU0234570918.USD":"高盛全球核心股票组合Acc Close","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","LU0889566641.SGD":"FTSF - Templeton Shariah Global Equity A Acc SGD","MET":"大都会人寿","IE00BVYPNV92.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) ACC","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC"},"translate_title":"Johnson & Johnson (JNJ.US) announced that the EGFR/c-MET dual antibody \"evantuzumab\" has been approved for a new indication in China","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JNJ":1,"MET":1},"content_text":"智通財經APP獲悉，8月8日，強生(JNJ.US)宣佈EGFR/c-MET雙抗「埃萬妥單抗」(Amivantamab)在國內獲批一項新適應症，聯合蘭澤替尼適用於攜帶表皮生長因子受體(EGFR)19號外顯子缺失或21號外顯子L858R置換突變的局部晚期或轉移性非小細胞肺癌(NSCLC)成人患者的一線治療。2025年2月，該藥首次在國內獲批，用於EGFRex20ins突變NSCLC一線治療。2025年4月，該藥在國內獲批一項新適應症，聯合化療用於EGFRTKI經治後局部晚期或轉移性NSCLC患者治療。本次是埃萬妥單抗在國內獲批的第3項適應症。埃萬妥單抗最早於2021年5月在美國首次獲得加速批准上市。迄今，圍繞非小細胞肺癌這一重磅癌種，埃萬妥單抗在全球範圍內已獲批4項適應症","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}